Episode 4: Accelerated Regulatory Pathways and Patient Access

February 11, 2020 PAREXEL

In this episode, Parexel’s Mwango Kashoki, a former FDA regulator, and Richard Macaulay, who specializes in market access challenges, join Alberto Grignolo to discuss expedited regulatory pathways and how they can impact payer evaluation. In particular, the discussion focuses on how the gap between regulatory approval and reimbursement can affect patient access to new therapies and how new models are being developed to address this dilemma.

Previous Article
Episode 5: CAR-T: How far have we come and where are we going?
Episode 5: CAR-T: How far have we come and where are we going?

In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 ...

Next Article
Episode 3: Bridging the Gap – How Minimizing Patient Barriers Can Improve Clinical Research
Episode 3: Bridging the Gap – How Minimizing Patient Barriers Can Improve Clinical Research

In this episode Alberto Grignolo, Corporate Vice President, Parexel, Sy Pretorius, Executive Vice President...